MedTrace Logo

Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome

NCT02617095 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2017-03-08

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy and safety of T2762 versus Optive® in the treatment of moderate to severe Dry Eye Syndrome.

Conditions

  • Dry Eye Syndrome

Interventions

DEVICE

T2762

One drop in each eye 3 to 6 times daily

DEVICE

Optive

One drop in each eye 3 to 6 times daily

Sponsors & Collaborators

  • Laboratoires Thea

    lead INDUSTRY

Principal Investigators

  • Frank Larkin, Professor · Moorfields Eye Hospital -162 city road - London

  • Friedrich KRUSE, Professor · Augenklinik mit Poliklinik - Swabachanlage 6 - 91054 Erlangen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-06-30
Completion
2016-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02617095 on ClinicalTrials.gov